Recombinant baculovirus displayed vaccine: a novel tool for the development of a cross-protective influenza H5N1 vaccine.
The rapid evolution of new sublineages of H5N1 influenza in Asia poses the greatest challenge in vaccine development for pre-pandemic preparedness. To overcome the antigenic diversity of H5N1 strains, multiple vaccine strains can be designed based on the distribution of neutralizing epitopes in the globular head of H5 hemagglutinin (HA). Recently, we selected two different HAs of H5N1 strains based on the neutralizing epitopes and reactivity with different neutralizing antibodies. The HAs of selected vaccine strains were individually expressed on the baculovirus envelope (bivalent-BacHA) with its native antigenic configuration. Further, oral delivery of live bivalent-BacHA elicited broadly reactive humoral, mucosal and cell-mediated immune responses and showed complete protection against antigenically distinct H5N1 strains in mice. The strategy for the vaccine strain selection, vaccine design and route of administration will provide an idea for development of a widely protective vaccine against highly pathogenic H5N1 for pre-pandemic preparedness.
Animal Health Biotechnology; Temasek Life Sciences Laboratory; National University of Singapore; Singapore, Singapore.
Mookkan
M
Prabakaran
Animal Health Biotechnology; Temasek Life Sciences Laboratory; National University of Singapore; Singapore, Singapore; Department of Microbiology; Faculty of Medicine; National University of Singapore; Singapore, Singapore.
Jimmy
J
Kwang
D000818:Animals; D056738:Cross Protection; D005260:Female; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000276:immunology*; D053124:Influenza A Virus, H5N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000276:immunology*; D009976:Orthomyxoviridae Infections / Q000517:prevention & control*
D019267:Hemagglutinin Glycoproteins, Influenza Virus; D007252:Influenza Vaccines
H5N1; cellular immunity; cross-protection; pre-pandemic; vaccine selection